造影前需要停用二甲双胍?6大问题一文汇总!

2021-11-12 MedSci原创 MedSci原创

这些要点不得不知!

二甲双胍应用于临床已有 60 余年历史,是目前全球应用最广泛的口服降糖药之一,一直屹立于糖尿病治疗的王者地位。作为一线降糖药物,二甲双胍还具有心血管保护、抗肿瘤、治疗多囊卵巢综合征 、改善肠道菌群等作用。然而,二甲双胍的临床应用中,仍存在一些疑惑困扰临床医生,本文就常见问题进行梳理。

1、二甲双胍能否用于心衰?

心衰是各种心脏疾病发展的终末阶段。由于可引起乳酸酸中毒,二甲双胍既往一直被禁止用于心衰患者。近年来,诸多研究显示,二甲双胍在慢性心衰患者中的安全性

2018ADA糖尿病指南建议,如果肾功能正常,二甲双胍可用于慢性稳定性心衰患者。《2018年二甲双胍临床映红中国专家共识》建议,禁止用于急性和不稳定性心衰患者 。欧洲版和中文版二甲双胍说明书中已删除慢性心力衰竭的禁忌证。

2、造影前需要停用二甲双胍?

患者造影或全身麻醉术前停用二甲双胍。向血管内注射碘化造影剂可能导致肾功能衰竭,引起二甲双胍蓄积,增加乳酸酸中毒的风险。

中度肾功能不全 eGFR 4559 ml/min·1. 73 m2 )]患者,在注射碘化造影剂及全身麻醉术前 48 h 必须停止服用二甲双胍,在检查完成至少 48 h 后且仅在再次检查肾功能无恶化的情况下才可以恢复服用。

3、二甲双胍能否降压降脂?

二甲双胍通过有效改善糖尿病和非糖尿病患者的IR,降低基础和负荷后胰岛素水平,起直接或间接的心血管保护作用。心血管疾病的风险因素包括血脂异常、IR、肥胖 、高血压 、非酒精性脂肪性肝病 NAFLD)等。

二甲双胍目前已被证实可降低血糖、改善NAFLD IR(尤其是肝脏和肌肉)、减轻体重、改善血脂和抗凝等。研究显示,二甲双胍可显著降低 T2DM 患者血浆 TGLDL⁃C TC 水平,但对 HDL⁃C 改变不明显。

当然,值得注意的是,糖尿病患者如果合并高血压或者高血脂,可采用二甲双胍进行降糖治疗,但千万不能因二甲双胍有助于降压降脂,就擅自停用降压药或降脂药。

4、二甲双胍什么时间服用最好?

目前,国内外主要有单一成分的二甲双胍普通片(250 mg/片、500 mg/片或 850 mg/片)、二甲双胍缓释片或胶囊(500 mg/ 500 mg/胶囊)、二甲双胍肠溶片或胶囊(250/ 500 mg/胶囊)、二甲双胍粉剂,以及与其他口服降糖药(如磺脲类药物或 DPP⁃4 抑制剂)组成的复方制剂。

二甲双胍的剂量调整原则为小剂量起始,逐渐加量。开始时 服用 5001000 mg/dl2 周后加量至最佳有效 剂量 2000 mg/d 或最大耐受剂量。二甲双胍可在 进餐时服用或餐后立即服用。

5、二甲双胍禁忌症有哪些?

尽管众多指南一致推荐二甲双胍用于 2 型糖尿病患者降糖治疗首选用药,但仍有一部分人群不适用:

1)中度(3b 级)和严重肾衰竭或肾功能不全[CrCl 45 ml/min eGFR45 ml/min∙1. 73 m2 )];

2)可造成组织缺氧的疾病(尤其是急性或慢性疾病 的恶化),如失代偿性心力衰竭、呼吸衰竭、近期发 作的心肌梗死、休克;

3)严重感染和外伤、外科大 手术、低血压等;

4)已知对盐酸二甲双胍过敏者;

5)急性或慢性代谢性酸中毒,包括有或无昏迷的 DKADKA 需用胰岛素治疗);

6)酗酒者;

7)接 受血管内注射碘化造影剂者,可暂时停用本品;

8)维生素 B12、叶酸缺乏未纠正者。

6、二甲双胍不良反应有哪些?

二甲双胍常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不 良、腹部不适及头痛,发生于治疗早期,多数患者可耐受。随着治疗时间的延长,上述不良反应可基本消失。

小剂量起始,逐渐加量,适时调整剂量,非缓释制剂分次随餐服用,或改成 1 /d 的缓释制剂,可减少胃肠道反应二甲双胍本身无肝、肾毒性。

参考文献

1.母义明, 纪立农, 李春霖,. 二甲双胍临床应用专家共识(2018年版)[J]. 中国糖尿病杂志, 2019, 027(003):161-173.

2.王健, 刘广忠, 白楠,. 二甲双胍在心血管疾病防治中的作用[J]. 国际心血管病杂志, 48(1):5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1494189, encodeId=b684149418986, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sun Nov 14 06:51:46 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069833, encodeId=cee4106983384, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Sat Nov 13 10:16:33 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069814, encodeId=05d2106981436, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 13 09:01:20 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069813, encodeId=647610698139a, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f9c5702141, createdName=ms6000001711810670, createdTime=Sat Nov 13 08:58:47 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069812, encodeId=eaee10698123f, content=沙利铂常见的剂量限制性毒性。重要的是,, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sat Nov 13 08:56:29 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069714, encodeId=e6d61069e148f, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8b5623723, createdName=ms6000000656440728, createdTime=Fri Nov 12 18:53:50 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-14 sodoo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1494189, encodeId=b684149418986, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sun Nov 14 06:51:46 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069833, encodeId=cee4106983384, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Sat Nov 13 10:16:33 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069814, encodeId=05d2106981436, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 13 09:01:20 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069813, encodeId=647610698139a, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f9c5702141, createdName=ms6000001711810670, createdTime=Sat Nov 13 08:58:47 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069812, encodeId=eaee10698123f, content=沙利铂常见的剂量限制性毒性。重要的是,, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sat Nov 13 08:56:29 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069714, encodeId=e6d61069e148f, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8b5623723, createdName=ms6000000656440728, createdTime=Fri Nov 12 18:53:50 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-13 向药师

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1494189, encodeId=b684149418986, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sun Nov 14 06:51:46 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069833, encodeId=cee4106983384, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Sat Nov 13 10:16:33 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069814, encodeId=05d2106981436, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 13 09:01:20 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069813, encodeId=647610698139a, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f9c5702141, createdName=ms6000001711810670, createdTime=Sat Nov 13 08:58:47 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069812, encodeId=eaee10698123f, content=沙利铂常见的剂量限制性毒性。重要的是,, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sat Nov 13 08:56:29 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069714, encodeId=e6d61069e148f, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8b5623723, createdName=ms6000000656440728, createdTime=Fri Nov 12 18:53:50 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-13 ms9000001258055198

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1494189, encodeId=b684149418986, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sun Nov 14 06:51:46 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069833, encodeId=cee4106983384, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Sat Nov 13 10:16:33 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069814, encodeId=05d2106981436, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 13 09:01:20 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069813, encodeId=647610698139a, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f9c5702141, createdName=ms6000001711810670, createdTime=Sat Nov 13 08:58:47 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069812, encodeId=eaee10698123f, content=沙利铂常见的剂量限制性毒性。重要的是,, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sat Nov 13 08:56:29 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069714, encodeId=e6d61069e148f, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8b5623723, createdName=ms6000000656440728, createdTime=Fri Nov 12 18:53:50 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-13 ms6000001711810670

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1494189, encodeId=b684149418986, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sun Nov 14 06:51:46 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069833, encodeId=cee4106983384, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Sat Nov 13 10:16:33 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069814, encodeId=05d2106981436, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 13 09:01:20 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069813, encodeId=647610698139a, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f9c5702141, createdName=ms6000001711810670, createdTime=Sat Nov 13 08:58:47 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069812, encodeId=eaee10698123f, content=沙利铂常见的剂量限制性毒性。重要的是,, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sat Nov 13 08:56:29 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069714, encodeId=e6d61069e148f, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8b5623723, createdName=ms6000000656440728, createdTime=Fri Nov 12 18:53:50 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-13 查查佳佳

    沙利铂常见的剂量限制性毒性。重要的是,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1494189, encodeId=b684149418986, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sun Nov 14 06:51:46 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069833, encodeId=cee4106983384, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Sat Nov 13 10:16:33 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069814, encodeId=05d2106981436, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 13 09:01:20 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069813, encodeId=647610698139a, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f9c5702141, createdName=ms6000001711810670, createdTime=Sat Nov 13 08:58:47 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069812, encodeId=eaee10698123f, content=沙利铂常见的剂量限制性毒性。重要的是,, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sat Nov 13 08:56:29 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069714, encodeId=e6d61069e148f, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8b5623723, createdName=ms6000000656440728, createdTime=Fri Nov 12 18:53:50 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-12 ms6000000656440728

    好文!

    0

相关资讯

Diabetes Obes Metab:二甲双胍单药治疗2型糖尿病和既往3期慢性肾病的疗效

二甲双胍对3期CKD (CKD3)或估计肾小球滤过率(eGFR)为30 - 59 mL/min/1.73 m2的患者是安全的。

万万没想到,“神药”二甲双胍会在这“小病”遇滑铁卢?

DARU Journal of Pharmaceutical Sciences:二甲双胍治疗纤维囊性乳腺病:一项安慰剂对照随机临床试验

二甲双胍普通片、缓释片和肠溶片,有哪些区别?

二甲双胍是治疗2型糖尿病的常用药,在国内外多个治疗指南中被列为一线降糖药物。该药物降糖作用确切、低血糖风险小、价格较低,是目前应用最广泛的降糖药物之一。

OMCL:卒中前应用二甲双胍对2型糖尿病脑出血患者1年预后的影响

二甲双胍是治疗2型糖尿病的一线药物。它可以预防糖尿病并发症。最近的研究已经证实二甲双胍具有抗氧化作用。

Cardiovasc Diabetol:比较恩格列净+利格列汀与二甲双胍+甘精胰岛素联合降糖方案对肾脏血流动力学影响的差异

2型糖尿病在全世界的患病率正在逐渐增加。二甲双胍和胰岛素的联合治疗被认为是治疗2型糖尿病的有效和成熟的联合疗法。